Bio Screening Industry News

Healthcare company AstraZeneca Plc (AZN: News, Chart, Quote ,AZN.L: News, Chart, Quote ) said Friday that it signed an innovative new partnership with the National Cancer Centre Singapore, or NCCS, and the National University Hospital, or NUH, for development of anti-cancer compounds. The collaboration is spelt out in a Memorandum of Understanding, or MOU.

As per the MOU, AstraZeneca and the Singapore institutions will enter into a collaborative agreement that spans both clinical and pre-clinical development activities.

AstraZeneca noted that the partnership also includes a Training Programme placement with the Manchester Cancer Research Centre, with whom AstraZeneca has a formal research alliance. Singapore Economic Development Board partly supports the training programme. The purpose of the training programme is to train a pool of clinical research professionals for both private-sector and public-sector research labs.

According to AstraZeneca, the partnership aims to further build its drug development capabilities in Asia and ultimately accelerate access to new medicines of potential benefit to patients with inoperable Hepatocellular Carcinoma, or HCC. HCC is a cancer that is particularly prevalent in Asia and accounts for approximately one million deaths annually worldwide.

Under the terms of the clinical development collaboration, NCCS and NUH can access AstraZeneca compounds that have already undergone initial clinical testing in the West.

The institutions have already identified AstraZeneca’s two compounds for clinical screening in inoperable HCC during 2008 and 2009. The company stated that more compounds would be made available at a rate of one per year, for the duration of the partnership, which exists until 2012.

For both clinical and pre-clinical activities, AstraZeneca maintained the alternative to presume further development and marketing of all drugs made available as part of the partnership deal.

AZN closed Thursday’s regular trade at $49.04, up $0.34, on a volume of 1.2 million shares.

The ICDDD 2008 is going to be the first major international conference and exhibition of this series, which aims to present cutting edge advances in various disciplines of drug design and discovery that have been recently achieved. Over 400 leading industrial and academic experts will present their findings in the form of lectures and poster presentations at this four-day conference. The ICDDD 2008 will offer an in-depth assessment of the challenges involved in the dynamic and fast moving field of drug discovery and development. It will bring together leading chemists, pharmacologists, biotechnologists, and other allied professionals to discuss and present the latest important developments in drug design and discovery.

The major topics of discussion related to drug design and discovery will include: Cancer; Cardiovascular Diseases; CNS; Pharmacogenomics; Protein & Peptides; Inflammation & Allergy; Drug Delivery & Safety; Drug Discovery Informatics; Drug Metabolism; Medicinal and Combinatorial Chemistry; Nanotechnology; Emerging Biomarkers & Drug Targets; Case Studies of Successful Drug Discovery and Development.

Dubai, the host city, is the region’s business and tourism centre which is connected to all international markets. The city is also famous as the regional trading hub and gateway to the rest of the Middle East. The visitors coming to Dubai can enjoy a whole range of different experiences which includes elements of adventure, contrast, discovery and surprise. Dubai World Trade Center, the venue of the conference, offers a comprehensive range of facilities catering to all types of meetings and major international conventions.

Advances in peptide and protein researches are occurring at an ever increasing pace, in a wide range of fields and scientific disciplines. At this exciting time, it is especially important to promote scientific and technological exchange and cooperation at the international level.

To establish of a new educational and networking platform for protein and peptide sciences for international academic and industrial institutions and professionals in the area, PepCon Committee has assembled an exciting scientific program, PepCon-2008, of local and international invited speakers, covering the areas of cutting edge peptide and protein researches. More than 500 participants are expected, including 300 scientists from academic, industrial and government research institutions, 100 best local and international academic and medical research institutions as well as 80 world-famous bio-pharmaceutical and instrumentation industries. The conference will be held in Shenzhen, China on April 22-24, 2008 and will take the form of lectures, workshops, round table conferences and posters around the theme of Peptide & Protein Technology: From Concept to Market .

Featuring Six Tracks:

—- Great Minds and Innovations —-

Track I: Human Proteome Technologies- Deciphering Genome with powerful tools of Proteomics
Session 1: Frontier of Emerging Human Proteome Technologies
Session 2: Breakthrough in Major Disease Proteomics and System Biology
Session 3: Bioinformatics and Structural Proteomics
Session 4: Industry-Sponsored Symposia on Proteomics
Session 5: Protein/Peptide Structure Activity and Interaction

Track II: Protein/Peptide Biomarker Discoveries- Essential Pathway to Seek Specific Solutions
Session 6: Biomarkers in Early Drug Development
Session 7: Biomarkers in Clinical Development
Session 8: Biomarkers for Molecular Diagnostics
Session 9: Biomarker Testing and Analysis Technologies Development

Track III: Protein /Peptide Drug Discovery - Build up New Product Pipeline for Severe Diseases
Session 10: From CADD to Booming Peptide Drug Development
Session 11: Peptide / Protein as Anti-Cancer Agents
Session 12: Peptide / Protein as Anti-Infective Drugs
Session 13: Proteins/Peptides for CNS Diseases
Session 14: Proteins/Peptides For Cardiovascular & Cerebrovascular Disease
Session 15: Peptide / Protein Drug Delivery Technology

—- Demand on Improving Productivities —-

Track IV: Solutions to Antibodies/Vaccines- Off-shore Operation Opportunities
Session 16: Protein and Peptide Vaccine Research and Development
Session 17: Outsourcing Antibody Development and Production
Session 18: Investment and Business Trends Driving Biotechnology

Track V: Bioprocesses for Industrial Proteins- Riding on the Third Wave
Session 19: Rising Industrial Biotechnology for Large Scale Manufacturing & Contract Outsourcing
Session 20: New Expression Systems: Cell Line & Cell Culture Engineering
Session 21: Accelerating Production of Commercialized Proteins and Enzymes

Part VI: Renaissance of Peptide Market-Cost-Effective for Success
Session 22: Increasing Efficiency of Peptide Synthesis and Manufacturing
Session 23: off-Shore Customized Preparation/Production for Cost-Effective Therapeutics Development
Session 24: Technology Transfer for Protein/Peptide

www.bitlifesciences.com/Pepcon2008/

Bio Conferences 2008

BIT Life Sciences

Eye for Pharma launches New live webinar aimed at Re engineering Physician Relationship Models

-    Features NEW Research on Physicians’ Experience Preferences and Sales Force Ratings.  .
-    Takes place 26th September 2007 12.00 EST / 18.00 CET

31st August 2007 London,

Physicians today want a new set of experiences from pharma, an integrated mix that includes patient support, educational programs and practice management services, as well as effective representative interactions.
The vast majority of companies recognize the need to transition to a service model that meets physicians’ new expectations. But most still struggle with how to move from traditional sales approaches to a physician-centric orientation.
EyeforPharma, world renowned leader in providing business strategy information and conferences for the Pharmaceutical Industry has announced an ALL NEW webinar called
‘Re-Engineering Physician Relationships:
Putting the New Service Model into Action
The  webinar will feature new research conducted with Physicians to understand exactly what doctors want, what changes are they seeing in the Pharma market and who is not delivering. Expert help will also be given on how to transition to a successful Physician -centric model.
Key speakers include
Andrew Brana, Senior Global Consultant, Sales Performance Optimization, TNS Healthcare
Simon Roberts, Strategic Partnerships/Market Access, Roche
Tobias Weizel, Sales & Marketing Effectiveness, Amgen
Gregg Ciarelli, Executive Director - Sales Administration, Boehringer Ingelheim
Brad Fackler, Executive Vice President of Commercial Operations, Sucampo Pharmaceuticals

The webinar will be of particular interest where companies are already thinking about or already implementing Physician-Centric Service Model. Attendees will discover what changes doctors are reporting in their rep interactions, learn which sales forces doctors say deliver the best experiences and understand how to create a successful physician-centric model .

The webinar will take place 26th September 2007 -
12.00 EST / 18.00 CET
For more information visit www.eyeforpharma.com/virtual/salesmodel/

About EyeforPharma

Eyeforpharma is a global  pharmaceutical business strategy information provider with a highly reputable and worldwide presence in the Pharma industry. It is renowned for producing top level conferences that attract the highest level of speakers to deliver presentations on cutting edge pharmaceutical business strategies. We provide business intelligence and analysis online at www.eyeforpharma.com and through an email briefing twice a month. Eyeforpharma also has a very strong foothold in the European, US and Japanese markets.

Advances in peptide and protein researches are occurring at an ever increasing pace, in a wide range of fields and scientific disciplines. At this exciting time, it is especially important to promote scientific and technological exchange and cooperation at the international level.

To establish of a new educational and networking platform for protein and peptide sciences for international academic and industrial institutions and professionals in the area, PepCon Committee has assembled an exciting scientific program, PepCon-2008, of local and international invited speakers, covering the areas of cutting edge peptide and protein researches. More than 500 participants are expected, including 300 scientists from academic, industrial and government research institutions, 100 best local and international academic and medical research institutions as well as 80 world-famous bio-pharmaceutical and instrumentation industries. The conference will take the form of lectures, workshops, round table conferences and posters around the theme of Peptide & Protein Technology: From Concept to Market .

The sessions will be tailored around:

Part Ⅰ : Emerging Enabled Technologies
1 Proteomics
2 Structure and Activity Relationship
3 Folding Misfolding and Structure with Disease
4 Peptide Materials

Part Ⅱ : Peptide / Protein Drug Discovery
1 Protein and Peptide in Immunity Studies
2 Protein Receptor and Drug Target
3 Peptide / Protein Drug Delivery Technology
4 Protein / Peptide as Diagnostic Tools
5 Protein/Peptide Vaccine

Part Ⅲ : Peptide / Protein Based Therapeutics
1 Peptide / Protein in Anti-Tumour
2 Peptide / Protein in Anti-Infection
3 Protein/Peptide Drug in CNS
4 Protein in Cardiovascular & Cerebrovascular Disease

Part Ⅳ : BioProcess for Peptide / Protein
1 Protein and Peptide Design & Expression
2 New Technologies in Protein Peptide Synthesis and Analysis

Part Ⅴ : Business Development
1 Outsourcing Service for Protein/Peptide
2 Market Research of Protein/Peptide Drug and Health Care Products

The conference will be held in Shenzhen during April 19-21, a world-renowned coastal city in southern China , Hong Kong being shortly near in the south. During the April 22-23, we arrange a two-day tour, “Charming Sanya, Romantic Heaven” , in Sanya of Hainan Island. The region is famous for beautiful local scenery, beaches, temples and rich ethnic folklore and at this time of the year you will be able to enjoy the weather and surroundings of this beautiful region of China , at their finest.

http://www.bitlifesciences.com/Pepcon2008/

The market for in vitro toxicology testing is approximately $200 million and expected to grow to more than $300 million by 2005. 90% of compounds fail in drug development because of four reasons. 41% of those fail because of poor ADME; 31% because of insufficient efficacy; 22% because of toxicity; and only 6% because of market and/or commercialization complications. The earlier in the development process that an inadequate compound can be removed, the less time and money wasted, usually on the order of five to ten years and hundreds of millions of dollars.

The triage process thus represents a large opportunity with significant unmet needs, and new technologies are defining and expanding this market. Triage starts immediately after primary high-throughput screening, and the market opportunity for re-screening of hits is approximately $190 million worldwide and expected to grow to more than $250 million by 2005. The market opportunities for toxicology and ADME currently total approximately $3 billion, most of which is spent on animal studies. The market for in vitro toxicology testing, the segment within secondary screening, is approximately $200 million and expected to grow more than $300 million by 2005. The market for in vitro ADME testing represents a conversation opportunity and is forecasted to remain relatively stable.

Amman, 03 July (Petra)–Specialists, participating in a one day workshop on bird flue disease, on Monday affirmed the importance of communication strategies between health sector and mass media in the field of confronting bird flue. The workshop, organized by the Ministry of Health (MOH) in cooperation with UN ICEF and WHO, is meant to further strengthen communication and information exchange between governmental and non-governmental institutions and the concerned international organizations concerning bird flue.

UNICEF communication and media Bureau Hend Mango pointed out that since the the disease appeared on the world level, the number of cases reached 228 which lead to 130 deaths.

Istanbul, Turkey - August 29 - September 2, 2006

The ISMC-2006 Symposium will be organized by the Turkish Association of Pharmaceutical and Medicinal Chemistry under the auspices of the European Federation for Medicinal Chemistry (EFMC).

This symposium is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance, which varies between 1200 and 1500 participants from all over Europe, but also from the United States and Asia.

The Symposium will focus on important new scientific and technological developments in the drug discovery process; particularly those relevant to medicinal chemistry. The meeting will create an environment for in-depth, informed discussions highlighting the importance of medicinal chemistry in the pharmaceutical industry, academia and drug research. It will also provide opportunities to re-emphasise the crucial position of medicinal chemistry in the drug discovery process and its pivotal role in linking and exploiting the associated biological sciences. Therefore, the ISMC-2006 intends to create a forum for all scientists interested in medicinal chemistry and related fields.

More details regarding the participation and the scientific program are available via the symposium website: www.ismc2006.org

Westborough, MA, October 17, 2005 – The BioProcess International™ Asia-Pacific conference
and exhibition to be held in Singapore next month will address the needs of Asian, American, and
European executives and scientists who are looking for global alliance and technological
innovations, as well as best practices to improve their bioprocessing techniques and benchmark
their manufacturing capabilities and skills. The event will be held from November 7-9, 2005 at The
Shangri-La Hotel in Singapore.

“Many operations in the development of biopharmaceuticals have moved to Asia” said Scott M.
Wheelwright, Ph.D., President, Strategic Manufacturing Worldwide Inc., USA; and a member of
the event’s Scientific Advisory Board. “Even with lower efficiencies, a company can lower its labor
costs by a factor of three by moving operations to a lesser-developed country. And the lower labor
rates translate into lower capital costs because the expense of facility construction and
equipment contains a significant labor component.”

In his article published in the October issue of the premier BioProcess International™ magazine,
Scott further elaborates that in China, the production of biopharmaceuticals has grown at a rate of
5-10% over the past few years and is expected to continue to expand at about 10% per year;
while in India, one observer estimates the industry has been growing at 25% for the past three
years and expects to double from the current $800 million over the next three years.

Whether you’re in upstream or downstream processing, whether you’re a business development
executive or the head of bioprocessing and manufacturing, you don’t want to miss this opportunity
to:

Find out how you can reduce your capital and labor costs
Meet potential collaborators, find out who’s who and understand the market landscape of
the biopharmaceutical industry in Asia
Hear about the scientific and regulatory challenges of biologics in Asia
Benchmark and scale up your production processes with efficiency and quality
Gain best practices in upstream and downstream process development and apply them
to your production needs
These and many more exciting topics will be addressed at the BioProcess International™ Asia
Pacific conference and exhibition in Singapore. Carefully researched with scientific advisors, this
event is meant to enable executives and scientists from all over the world to come together to
learn about opportunities for business collaborations and share insights into scientific advances.
This is your chance to make and leave your mark in the Asia-Pacific biopharmaceutical industry.

For detailed information about the event, and to register online, visit:
http://www.IBCLifeSciences.com/BPI/Asia